Coronary

View the latest content related to this topic

News Daily News

Type 2 MI Diagnoses on the Rise, but Best Course of Action Unknown

With a mix of causes and comorbidities, type 2 MI patients do better than type 1 early on, then face worse long-term outcomes.

Caitlin E. Cox

October 08, 2025

Slides

See all

Presentation ESC 2025

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

Presenter: David Newby

September 03, 2025

Presentation ESC 2025

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

Presenter: Anders Jeppsson

September 01, 2025

Presentation ESC 2025

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Presenter: Subodh Verma

September 01, 2025

Presentation ESC 2025

SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease

Presenter: Mårten Falkenberg

August 31, 2025

Presentation ESC 2025

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

Presenter: Duk-Woo Park

August 31, 2025

News

See all

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

By Michael O'Riordan

October 10, 2025

News Conference News TCT 2025

What’s Going to Be Hot at TCT 2025

By Michael O'Riordan

October 09, 2025

News Daily News

Type 2 MI Diagnoses on the Rise, but Best Course of Action Unknown

By Caitlin E. Cox

October 08, 2025

News Daily News

Novel Biomarker GDF-15 Helps Risk-Stratify Patients With Suspected ACS

By Todd Neale

October 03, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

By Michael O'Riordan

October 02, 2025

ACC 2025

March 29

March 31, 2025

CTO 2025

February 28

March 01, 2025

THT 2025

February 11

February 13, 2025

Videos on This Topic

See all

Advertisement

Coronary

Type 2 MI Diagnoses on the Rise, but Best Course of Action Unknown

Slides

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

What’s Going to Be Hot at TCT 2025

Type 2 MI Diagnoses on the Rise, but Best Course of Action Unknown

Novel Biomarker GDF-15 Helps Risk-Stratify Patients With Suspected ACS

Risk Factors Present in Nearly All Patients Who Develop CVD

More on This Topic

Conference Coverage

ACC 2025

CTO 2025

THT 2025

Videos on This Topic

Advertisement

Coronary

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content